Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899808|
Recruitment Status : Withdrawn (not "applicable clinical trial")
First Posted : May 12, 2009
Last Update Posted : May 29, 2015
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.
|Condition or disease|
|Hematopoietic/Lymphoid Cancer Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific|
- Determine local-regional control in patients undergoing radiation therapy for cancer, as a function of expression of specific molecular/genetic markers.
- Determine complications of radiation therapy for patients undergoing radiation therapy for cancer.
OUTLINE: Previously collected tissue samples are analyzed using immunohistochemical staining and other molecular/genetic study methods to detect markers, including p53, cyclin D1, HER-2-neu, bcl-2/BAX, and EGFR. Patient charts are also reviewed with emphasis on local-regional relapse.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||May 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899808
|United States, New Jersey|
|Rutgers Cancer Institute of New Jersey - Robert Wood Johnson Medical School|
|New Brunswick, New Jersey, United States, 08903|
|Principal Investigator:||Bruce G. Haffty, MD||Rutgers Cancer Institute of New Jersey- Robert Wood Johnson Medical School|